CAS: 1903008-80-9; N-(5-((4-(4-((Dimethylamino)Methyl)-3-Phenyl-1H-Pyrazol-1-yl)Pyrimidin-2-yl)Amino)-4-Methoxy-2-Morpholinophenyl)Acrylamide

结构式图片

欧盟法规

REACH注册C&L通报

合成工艺路线路线简述

    📜4-氟-2-甲氧基-5-硝基苯胺置于盐酸,4-二甲氨基吡啶,Palladium On Activated Charcoal,甲酸铵,碳酸氢钠,三乙胺,N,N-二异丙基乙胺体系中,用 四氢呋喃,乙醇,二氯甲烷,N,N-二甲基乙酰胺,水,乙腈,正丁醇 用作溶剂,化学反应 35.0H,反应生成兰泽替尼
    参考文献: Intermediates Useful For The Synthesis Of A Selective Inhibitor Against Protein Kinase And Processes For Preparing The Same[fr] Intermédiaires Utiles Pour La Synthèse D'Un Inhibiteur Sélectif Vis-à-Vis De La Protéine Kinase Et Leurs Procédés De Préparation
    标题: Intermediates Useful For The Synthesis Of A Selective Inhibitor Against Protein Kinase And Processes For Preparing The Same[fr] Intermédiaires Utiles Pour La Synthèse D'Un Inhibiteur Sélectif Vis-à-Vis De La Protéine Kinase Et Leurs Procédés De Préparation
    摘要:本发明提供了用于合成氨基嘧啶衍生物或其药用盐的中间体,该衍生物具有选择性抑制蛋白激酶的活性,特别是对突变表皮生长因子受体的蛋白激酶具有抑制活性;以及制备这些中间体的方法.此外,本发明还提供了用于上述过程的新型中间体以及制备这些中间体的方法.

    海关参考信息

    专利信息


    专利号:US-11198684-B2
    优先权日:2017-07-28
    标 题 :Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
    发明人:OH SANG-HO; KHOO JA-HEOUK; LIM JONG-CHUL; LEE DOO-BYUNG; LEE JUNG-AE; LEE JUN-SUP; JU HYUN; SHIN WOO-SEOB; JEON SANG-SEOL
    权利人:YUHAN CORP
    摘要:The present invention provides intermediates useful for the synthesis of an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors; and processes for preparing the same. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

    专利号:US-2025289827-A1
    优先权日:2022-12-02
    标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
    发明人:YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
    权利人:C4 THERAPEUTICS INC
    摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

    专利号:US-12390420-B1
    优先权日:2024-10-22
    标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
    发明人:EGUCHI MASAKATSU
    权利人:BRYET US INC
    摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.

    专利号:WO-2019022487-A1
    优先权日:2017-07-28
    标题 :INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR TO PROTEIN KINASE AND METHODS FOR THEIR PREPARATION

    专利号:HR-P20220848-T1
    优先权日:2017-07-28
    标 题:INTERMEDIATES USEFUL FOR THE SYNTHESIS OF AMINOPYRIMIDINE DERIVATIVES, PROCEDURE FOR THEIR PRODUCTION, AND PROCEDURE FOR THE PRODUCTION OF AMINOPYRIMIDINE DERIVATIVES USING THEM

    专利号:CN-111032650-A
    优先权日:2017-07-28
    标题 :Novel intermediates that can be used in the synthesis of aminopyrimidine derivatives, methods for their preparation and methods for preparing aminopyrimidine derivatives using the same

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan- Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23. MARIPOSA Investigators. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. 18(6):639-647. doi: 10.2217/fon-2021-0923. Epub 2021 Dec 16. 41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. 35(9):805-816. doi: 10.1016/j.annonc.2024.05.541. Epub 2024 Jun 26. 29(10):2577-2585. doi: 10.1038/s41591-023-02554-7. Epub 2023 Sep 14.
    7: Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Şendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.

    合成参考文献


    摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2026).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知